男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Merck to invest more in country, sharpen focus on R&D, local tie-ups

By LIU ZHIHUA | China Daily | Updated: 2024-07-30 09:30
Share
Share - WeChat
A view of Merck's booth during an expo in Shanghai last month. [Photo/China Daily]

Merck will continue to invest in China, which is not only the second-largest consumer market in the world but also has rising innovation capability, said a senior executive of the German science and technology company.

"China is a significant market for us, for looking at innovation to bring it outside China and bringing our innovation into China," said Peter Guenter, a member of the executive board and CEO of Healthcare at Merck.

"We have done a lot of investments in China. Our commitment to China is clear. We will continue to grow, and we will continue to invest in the country."

The executive is deeply impressed by the remarkable changes in China's pharmaceutical market as it has "developed incredibly over the last 10 to 20 years, transforming from a generic industry focused on small molecules to one driven by innovation".

China has become very strong in technological innovation, as reflected by its rapid progress and innovation in the field of antibody-drug conjugates, he said.

China's huge potential as a major innovation hub holds great promise for Merck to collaborate with local partners, including startups, biotech and biopharma firms, and research institutes, to drive innovation forward, said Guenter.

"At a certain point in time, China could be the country from which innovation comes, truly first. I think that's the next frontier for the Chinese R&D ecosystem, to continue being very, very good at perfecting technologies, but also going upstream to find a new molecule for a new disease."

Citing various dynamics behind China's growing innovation drive that include well-educated talent and enabling regulatory environment, the executive spoke particularly highly of the clinical development pace in China.

The speed, agility and quality of the Chinese investigators who conduct clinical trials are remarkable, he said, adding the massive number of patients with unmet medical needs also contributes to the speedy drug development pace in the country.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 锡林浩特市| 元氏县| 图们市| 西和县| 长治县| 广河县| 湟中县| 方山县| 遂川县| 钟祥市| 沅陵县| 西华县| 安陆市| 巴彦县| 阜新市| 陈巴尔虎旗| 乐山市| 叙永县| 通城县| 阿鲁科尔沁旗| 惠州市| 郁南县| 潍坊市| 明光市| 林西县| 罗江县| 乌海市| 天全县| 孝感市| 宁晋县| 称多县| 吉首市| 耿马| 丹巴县| 瑞安市| 花莲市| 个旧市| 全椒县| 九龙县| 安新县| 顺昌县|